Europe Persistent Corneal Epithelial Defects Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2019
  • Europe
  • 350 Pages
  • No of Tables: 213
  • No of Figures: 41

Europe persistent corneal epithelial defects treatment market By Clinical Causes (Inflammatory Disease, Neurotrophic Keratitis (NK), Epithelial/Limbal Stem Cell Deficiency, Others), Type (Devices, Medication), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Hungary,  Lithuania, Austria, Ireland, Norway, Poland and Rest of Europe), Market Trends and  Forecast to 2027

Market Analysis and Insights: Europe Persistent Corneal Epithelial Defects Treatment Market

Persistent corneal epithelial defects treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with highest a CAGR of 5.1% in the forecast period of 2020 to 2027 and expected to reach USD 288.34 million by 2027. Increasing concern about Persistent corneal epithelial defects is the factors for the market growth.  

Persistent corneal epithelial defect is a multifactorial disorder occurs due to failure of corneal epithelialization mechanism which leads to the disturbance in the corneal surface and exposed the eyes vulnerable to the stromal ulceration, herpetic infections and scarring. Growing ageing population augmenting towards the PCED condition is augmenting the market growth.

Increased number of persistent corneal epithelial defect medication and devices offering from pharmaceutical manufacturers will accelerate the market growth. Large amount of research and development from manufacturers for developing persistent corneal epithelial defects treatment medication and devices to make it affordable are also expected to enhance the market growth. Strategic Initiatives by Persistent corneal epithelial defect medication and devices manufactures will further create new opportunities that impact this persistent corneal epithelial defects treatment market growth in the forecast period to 2027. For instance, In November 2018, Johnson & Johnson Vision Care, Inc.’s ACUVUE OASYS with Transitions Light Intelligent Technology has been awarded Best Inventions of 2018. The award will help company to increase its credibility in the market among patients as well as among healthcare professionals.

This persistent corneal epithelial defects treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Persistent Corneal Epithelial Defects Treatment Market Scope and Market Size

Europe persistent corneal epithelial defects treatment market is segmented on the basis clinical causes, type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Europe Persistent Corneal Epithelial Defects Treatment Market

  • On the basis of clinical causes, the market is segmented into epithelial/limbal stem cell deficiency, inflammatory disease, neurotrophic keratitis (NK) and others. Inflammatory diseases segment is dominating in the persistent corneal epithelial defects treatment market because inflammatory disease is one of the most common cause of persistent corneal epithelial disease (PCED) and high usage of medication as well as devices in the treatment.
  • On the basis of type, the market is segmented into devices and medication. Medical devices are dominating in the persistent corneal epithelial treatment market as these are more effective treatment method and these are available at low prices compared to the medications and most of the medications are present in the pipeline of the company so, the medical devices are the most available options present in the market. Due to all these reasons medical devices is dominating in the market.
  • On the basis of end-user, the market is segmented into hospitals, homecare, specialty clinics and others. Hospital segment is dominating the persistent corneal epithelial defects treatment market because of the high patient volume and high treatment rates. Medical devices are most commonly used treatment for the persistent corneal epithelial treatment and medical device usage needs surgery which can only be performed in hospital. Due to all these reasons hospitals are dominating in the market.
  • On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacy is dominating in the persistent corneal epithelial defects treatment market as more number of patients is treated in hospitals so there is increased demand of the treatment methods in hospital pharmacy. Additionally, some of the treatment products are only available in the hospital pharmacy as they require special storage options.

Persistent corneal epithelial defects treatment Market Country Level Analysis

Europe market is analysed and market size information is provided on the basis of clinical causes, type, end user, distribution channel and country as referenced above.

The countries covered in the persistent corneal epithelial defects treatment market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Hungary,  Lithuania, Austria, Ireland, Norway, Poland and rest of Europe in Europe.

Persistent corneal epithelial defects treatment market is growing due to increasing research and development of persistent corneal epithelial defects treatment medications and devices from it’s manufacturers to make affordable persistent corneal epithelial defects treatment medications and devices is expected to grow at the significant growth rate in the forecast period of 2020 to 2027 because of increasing aging population.

Persistent corneal epithelial defects treatment market is growing due to government initiatives to increase the awareness and research and development of persistent corneal epithelial defects treatment is expected to grow at the significant growth rate in the forecast period of 2020 to 2027. Additionally, Oxervate (Human Nerve Growth Factor) which one of the mostly potent drug for persistent corneal epithelial defects treatment, was first launched in Europe (in 2018).Germany is growing with the highest market share as this is a developed country and more number of pharmaceutical and device companies is present in the country. Additionally advancements of proteomics, genome technologies, and specific applications related to the mass spectrometry also have generated new prospects for research.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, and regulatory act and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Development of novel therapeutics by persistent corneal epithelial defects treatment manufactures to develop new therapeutics in persistent corneal epithelial defects treatment market

Persistent corneal epithelial defects treatment market also provides you with detailed market analysis for every country growth in installed base of different kind of products for persistent corneal epithelial defects treatments market, impact of technology using life line curves and changes in regulatory scenarios and their impact on the persistent corneal epithelial defects treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Persistent corneal epithelial defects treatment Market Share Analysis

Persistent corneal epithelial defects treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe persistent corneal epithelial defects treatment market.

The major players covered in the report are Dompé Farmaceutici S.p.A, Novartis AG, Allergan, Johnson & Johnson Services, Inc., Laboratoires THEA S.A.S, Almirall, S.A, Bausch Health, Integra LifeSciences Corporation, among other players domestic and Europe. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

For instance,

  • In March 2019, Johnson & Johnson Vision Care, Inc. has announced that ACUVUE OASYS is now available with Transitions Light Intelligent Technology in the U.S. The new TRANSITIONS in ACUVUE OASYS will help company to increase its market share as the product is first-of-its-kind photochromic contact lens.
  • In January 2019, Dompé farmaceutici S.p.A. has successfully performed first patient treatment with Oxervate (cenegermin-bkbj) eye drops, in the U.S. The completion of first treatment successfully is expected to increase Oxervate usage in the U.S.

Such investment and partnership other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for persistent corneal epithelial defects treatments through expanded model range

Customization Available : Europe Persistent Corneal Epithelial Defects Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 2 EUROPE INFLAMMATORY DISEASE IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 3 EUROPE NEUROTROPHIC KERATITIS (NK) IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 EUROPE EPITHELIAL/LIMBAL STEM CELL DEFICIENCY IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 EUROPE OTHERS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY REGION, 2018-2027 (USD MILLION)

TABLE 6 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY TYPE, 2018-2027 (USD MILLION)

TABLE 7 EUROPE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY REGION, 2018-2027 (USD MILLION)

TABLE 8 EUROPE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY TYPE, 2018-2027 (USD MILLION)

TABLE 9 EUROPE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY TYPE, 2018-2027 (UNITS)

TABLE 10 EUROPE PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 11 EUROPE CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 12 EUROPE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 13 EUROPE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 14 EUROPE PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 15 EUROPE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 16 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY END USER, 2018-2027 (USD MILLION)

TABLE 17 EUROPE HOSPITALS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 18 EUROPE HOMECARE IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 EUROPE SPECIALTY CLINICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 20 EUROPE OTHERS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY REGION, 2018-2027 (USD MILLION)

TABLE 21 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 22 EUROPE HOSPITAL PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 23 EUROPE RETAIL PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 EUROPE ONLINE PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 25 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,  BY COUNTRY 2018-2027 (USD MILLION)

TABLE 26 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 27 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 28 EUROPE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 29 EUROPE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 30 EUROPE PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 31 EUROPE CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 32 EUROPE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 33 EUROPE PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 34 EUROPE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 35 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 36 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 37 GERMANY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 38 GERMANY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 39 GERMANY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 40 GERMANY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 41 GERMANY PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 42 GERMANY CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 43 GERMANY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 44 GERMANY PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 45 GERMANY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 46 GERMANY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 47 GERMANY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 48 U.K. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 49 U.K. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 U.K. DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 U.K. DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 52 U.K. PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 53 U.K. CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 54 U.K. MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 55 U.K. PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 56 U.K. MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 57 U.K. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 58 U.K. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 59 FRANCE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 60 FRANCE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 FRANCE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 FRANCE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 63 FRANCE PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 64 FRANCE CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 65 FRANCE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 66 FRANCE PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 67 FRANCE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 68 FRANCE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 69 FRANCE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 70 ITALY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 71 ITALY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 72 ITALY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 73 ITALY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 74 ITALY PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 75 ITALY CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 76 ITALY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 77 ITALY PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 78 ITALY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 79 ITALY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 80 ITALY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 81 SPAIN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 82 SPAIN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 83 SPAIN DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 84 SPAIN DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 85 SPAIN PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 86 SPAIN CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 87 SPAIN MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 88 SPAIN PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 89 SPAIN MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 90 SPAIN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 91 SPAIN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 92 RUSSIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 93 RUSSIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 94 RUSSIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 95 RUSSIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 96 RUSSIA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 97 RUSSIA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 98 RUSSIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 99 RUSSIA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 100 RUSSIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 101 RUSSIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 102 RUSSIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 103 NETHERLANDS PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 104 NETHERLANDS PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 105 NETHERLANDS DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 106 NETHERLANDS DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 107 NETHERLANDS PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 108 NETHERLANDS CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 109 NETHERLANDS MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 110 NETHERLANDS PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 111 NETHERLANDS MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 112 NETHERLANDS PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 113 NETHERLANDS PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 114 SWITZERLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 115 SWITZERLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 116 SWITZERLAND DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 117 SWITZERLAND DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 118 SWITZERLAND PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 119 SWITZERLAND CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 120 SWITZERLAND MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 121 SWITZERLAND PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 122 SWITZERLAND MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 123 SWITZERLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 124 SWITZERLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 125 BELGIUM PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 126 BELGIUM PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 127 BELGIUM DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 128 BELGIUM DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 129 BELGIUM PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 130 BELGIUM CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 131 BELGIUM MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 132 BELGIUM PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 133 BELGIUM MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 134 BELGIUM PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 135 BELGIUM PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 136 TURKEY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 137 TURKEY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 138 TURKEY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 139 TURKEY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 140 TURKEY PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 141 TURKEY CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 142 TURKEY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 143 TURKEY PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 144 TURKEY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 145 TURKEY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 146 TURKEY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 147 AUSTRIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 148 AUSTRIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 149 AUSTRIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 150 AUSTRIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 151 AUSTRIA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 152 AUSTRIA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 153 AUSTRIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 154 AUSTRIA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 155 AUSTRIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 156 AUSTRIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 157 AUSTRIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 158 IRELAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 159 IRELAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 160 IRELAND DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 161 IRELAND DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 162 IRELAND PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 163 IRELAND CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 164 IRELAND MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 165 IRELAND PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 166 IRELAND MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 167 IRELAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 168 IRELAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 169 NORWAY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 170 NORWAY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 171 NORWAY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 172 NORWAY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 173 NORWAY PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 174 NORWAY CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 175 NORWAY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 176 NORWAY PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 177 NORWAY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 178 NORWAY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 179 NORWAY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 180 HUNGARY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 181 HUNGARY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 182 HUNGARY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 183 HUNGARY DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 184 HUNGARY PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 185 HUNGARY CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 186 HUNGARY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 187 HUNGARY PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 188 HUNGARY MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 189 HUNGARY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 190 HUNGARY PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 191 POLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 192 POLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 193 POLAND DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 194 POLAND DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 195 POLAND PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 196 POLAND CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 197 POLAND MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 198 POLAND PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 199 POLAND MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 200 POLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 201 POLAND PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 202 LITHUANIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 203 LITHUANIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 204 LITHUANIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 205 LITHUANIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 206 LITHUANIA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 207 LITHUANIA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 208 LITHUANIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 209 LITHUANIA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 210 LITHUANIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 211 LITHUANIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 212 LITHUANIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 213 REST OF EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions